StemCell Therapy

The past decade has seen significant advances in type 2 diabetes treatments, yet the long-term impact of these advances is not yet fully appreciated. The risk estimates currently available are derived from data that is more than 10 years old. The insurance industry underwrites customers with diabetes based on a range of factors, medical expertise and various medical studies.

The aim of this research project is to develop a deeper understanding of the risks associated with type 1 or type 2 diabetes, and the impact of recent improved treatments. It is hoped that this research will help the insurance industry appreciate and use current data and studies when considering diabetic risks, and ultimately could support individuals with diabetes to gain better access to insurance.

The call for tenders was issued on 1 June and organisations have until 12pm BST on 13 July to submit their proposals. This commissioned research will be overseen by a project steering group including representation from the IFoAs Diabetes Working Party and partner organisations. Independent academic guidance is also being provided by Cass Business School, City, University of London.

For further information onthis jointly commissioned ARC research project, please visitbit.ly/arcdiabetes

Read the original post:
An analysis of diabetes mortality and morbidity risk - The Actuary

This entry was posted on July 9, 2020 at 8:49 pm and is filed under Diabetes. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |